Document is current
Any future updates will be listed below
-
Authors
Gray-Gaillard, Elise F.
Shah, Ami A.
Bingham III, Clifton O.
Elisseeff, Jennifer H.
Murray, Joseph
Brahmer, Julie
Forde, Patrick
Anagnostou, Valsamo
Mammen, Jennifer
Cappelli, Laura C.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24 AR080217, P30 AR070254, K23 AR075872)
Donald B and Dorothy L Stabler Foundation
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
NIH Pioneer
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 23 March 2025
First Online: 1 April 2025
Declarations
:
: The study was approved by the Johns Hopkins institutional review board (IRB00263113).
: Not applicable.
: LCC received research funding from Bristol-Myers Squibb and has consulted for Amgen and Santa Ana. V.A receives research funding to Johns Hopkins University from Astra Zeneca and Personal Genome Diagnostics, has received research funding to Johns Hopkins University from Bristol-Myers Squibb and Delfi Diagnostics in the past 5 years, is an advisory board member for AstraZeneca and Neogenomics and receives honoraria from Foundation Medicine, Guardant Health and Personal Genome Diagnostics. V.A is an inventor on patent applications (63/276,525, 17/779,936, 16/312,152, 16/341,862, 17/047,006 and 17/598,690) submitted by Johns Hopkins University related to cancer genomic analyses, ctDNA therapeutic response monitoring and immunogenomic features of response to immunotherapy that have been licensed to one or more entities. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. JMammen has a research grant from Interpace Diagnostics. JB has research funding from Bristol-Myers Squibb and Astra Zeneca and is an advisory board member for Astra Zeneca. JCM consulted and advised for Janssen, Johnson & Johnson, Caris, iTeos Therapeutics; received honorarium from Curio Science, ION Oncology Practice Network, MJH Life Sciences, and NCODA, received research support to his institution from Merck.
